Development of Pharmacovigilance in AI Tool: Drug Safety Monitoring

Figure 1: Pharmacovigilance process

Figure 2: Role of  AI in Pharmacovigilance

5. The Importance of AI in pharmacovigilance

AI's significance in pharmacovigilance Interest in using artificial intelligence (AI) to enhance drug development and management is expanding. This includes crucial fields like pharmacovigilance (PV), which entails monitoring the security of pharmaceuticals after they are put on the market.  USDA (Food and Drug Administration) as "all scientific and data collection activities related to the detection, evaluation and understanding of adverse events."  Pharmacovigilance, as defined by the FDA, includes a wide range of scientific research techniques, clinical pharmacology studies, registries, individual case safety reports (ICSRs), and other approaches^{. (7)} The FDA is looking into how artificial intelligence might be used in a number of these fields, but the research in these areas is not yet advanced enough to warrant broad legislation.  The following factors led us to select this intriguing subject^{. (7)}

a) ICSRs continue to provide vital new security information and have a long history of revealing security threats.  After a medication is licensed, new safety issues frequently surface. ⁽⁷⁾

b) As the number of data sources that need to be reviewed for safety information increases and changes, industry and regulatory bodies process, decrease, and update the number of ICSRs for safety signals.  This puts more strain on the few security experts and raises expenses.  This overall tendency has been brought to light by an increase in the reporting of medications used to prevent and treat coronavirus illness 2019 (COVID-19^{) (7)}

c) Regulatory bodies around the world demand ICSR delivery, and standardization techniques boost productivity.

d) ICSRs will undoubtedly remain a crucial early warning mechanism for drug safety signals, especially for rare events, and will remain important in the solar environment sector for some time to come, even though safety assessment and recognition are becoming more popular.  indications derived from population-based data sources' estimates.

e) The current ICSR reporting methods have been modified, but it seems unclear that these modifications will be enough on their own^{. (7)}

6. Adverse Drug Reaction, Side Effect, and Adverse Event 

Any undesirable medical event that may occur when taking medication but does not always have a direct link to the therapy is considered an adverse event, So the World Health Organization says.  Any unintended result a pharmaceutical product that arises at dosages typically utilized by a patient and is associated with the drug's pharmacological characteristics is referred to as a side effect.  The World Health Organization has suggested that the word "adverse drug reaction" be used to refer to "a noxious and unintended reaction to a medicine, which occurs at doses normally used in man." According to the preceding descriptions, adverse drug occurrences might involve a variety of circumstances, ranging from medication errors to side effects and unanticipated drug reactions.  This can include events that occur during therapy but aren't directly brought on by the drug^{. (1)}

6.1. Procedure for Determining Causation in Adverse Drug Reactions

The process of figuring out the likelihood that a specific medication was the cause of an observed adverse event is known as causation evaluation.  Frequently employed instruments for this purpose include the ALDEN algorithm, the Naranjo Adverse Drug Reaction Probability Scale, and the WHO-UMC Causality Scale, which is specific to drug-induced epidermal necrolysis. In addition to causality assessment, there are specialized tools to evaluate the preventability (like the Thornton and Shamrock scale) and the intensity of adverse drug responses (ADRs) (like the Hartwig and Siegel's scale). In pharmacovigilance programs (PvP), We commonly employ the WHO-UMC causality scale in pharmacovigilance programs (PvP).  The latent period—the interval between beginning medication and the onset of symptoms—is used to establish the temporal association between drug intakes. Additionally, the negative response is credible, implausible, or reasonable.  The latency period can differ greatly according on the type of reaction, according to dermatologists.  Angioedema and urticaria, for instance, can appear minutes to hours later.  A drug response accompanied by eosinophilia and systemic symptoms (DRESS) may occur weeks or months later.  Drug-induced vasculitis can take years to manifest.  The delay times listed in Table 1 are only applicable to the first exposure. Upon re-exposure, reactions may occur more rapidly (within 24 hours), regardless of the type of reaction.⁽¹⁾ In cases of polypharmacy (patients taking multiple drugs), the suspected drug can often be identified by analyzing the timing between drug administration and symptom onset. For example, although a medication that Although the patient's sudden urticaria is unlikely to be caused by the medication they have been taking for weeks, it could be the cause of a reaction with a longer latency period, such as DRESS. The situation becomes more complex when multiple new drugs are started at the same time, and the patient develops an ADR. In such cases, the gold standard for identifying the causative drug is a rechallenge test—where the drug is reintroduced to observe recurrence of symptoms. However, this is usually unethical unless the medication is life saving and no suitable alternatives exist When multiple drugs are plausible causes, one can prioritize based on the known frequency of specific ADRs associated with each medication. This information is available on platforms like: Ephorates Micromedex^{. (1)} While the others are labeled as "possible," the medicine with the greatest known frequency of generating the reaction that was observed may be rated as "probable."  It's also critical to consider drug interactions, which can have negative consequences even when individual medications are well tolerated.  Febuxostat, for instance, can increase the toxicity of azathioprine by inhibiting xanthine oxidase, leading to elevated blood levels of azathioprine. Information about such interactions can also be found on Ephorates or Micromedex. Finally, pharmacovigilance programs encourage the reporting of all suspected ADRs, regardless of severity. Such reporting is essential for identifying new patterns of drug reactions and detecting rare adverse effects. ⁽¹⁾

Table 1: The average amount of time that passes between starting a medication and experiencing an adverse medication effect on the skin

Table 2: Typical medication linked to skin-related adverse medication response

7.  Clinical trials 

Randomized controlled trials (RCTs) have at times revealed serious and unexpe Table 1: Typical medications linked to cutaneous adverse drug reactions cted adverse effects of medications. For instance, the 1991 CAST trial showed that using antiarrhythmic drugs preventively after a heart attack increased death rates—contrary to prior assumptions. This finding was later supported by a systematic review. Other notable RCTs also uncovered harms: the ALLHAT trial found that doxazocin increased heart failure risk, while the SEAS trial linked ezetimibe to higher cancer mortality. In 2002, high doses of poetics were shown to raise mortality by 22% compared to lower doses. That same year, two large publicly funded RCTs on hormone replacement therapy (HRT) were halted early due to a higher incidence of breast cancer, strokes, and heart attacks in the HRT group. Despite weak supporting evidence, HRT had been widely prescribed for nearly a decade—leading to estimates of tens of thousands of breast cancer cases in the UK and hundreds of thousands in the U.S^.(12) over a 10-year span In 2004, following the withdrawal of Vioxx, meta-analyses revealed that other COX-2 selective NSAIDs like celecoxib and diclofenac also raised cardiovascular risk, possibly causing thousands of deaths annually in Europe. These examples highlight the urgent need for ongoing cumulative meta-analyses of individual patient data from both new and existing RCTs, as well as the importance of transparent and unbiased clinical research. Given the prevalence of selective reporting and scientific misconduct, it's argued that the European Medicines Agency (EMA) should be legally required to conduct such analyses. Since 2004, further adverse effects have been detected through meta-analyses of RCTs^{. (12)} These include increased suicidal thoughts and behaviors in children and adolescents taking SSRIs, suicide attempts with paroxetine in adults, heart attacks linked to rosiglitazone, and stroke and death in elderly patients using neuroleptics. Meta analyses of RCTs can also help confirm drug safety when safety signals emerge from other data sources. However, real-world risks are likely to be even higher than those observed in trials. These findings typically relate to widely used medications and serious health conditions, underlining their significant impact on public health. In this context, the meta-analysis of clinical trials represents a "third generation" approach to pharmacovigilance and has greatly advanced our understanding of the widespread harm medications can cause. ⁽¹²⁾

8.  Pharmacovigilance: past and present:  

Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have numerous duties, one of which is to safeguard and promote public health by evaluating and supervising medications intended for human use.  These regulatory bodies' responsibilities have changed over the past century to put patient safety and consumer protection first^{.  (15)} The FDA (Bureau of Chemistry) in the early 1900s concentrated its regulation efforts on foods due to the belief that they were more dangerous to the public than tainted or mislabeled medications.  Nonetheless, the 1938 Food, Medicine, and Cosmetic Act required that pharmaceutical labels have adequate directions for safe use and controlled cosmetics and medical equipment.  The changes made to this statute have allowed for the by regulating medications for human use, the FDA will keep improving its capacity to safeguard the public's health. A decentralized agency of The European Medicines Agency (EMA) was established in 1995 by the European Union (EU) To protect and improve the health of both humans and animals, Its primary duty is to supervise the assessment and administration of drugs meant for human and veterinary use.  A European pharmaceutical network comprising the European Commission, the European Parliament, over 40 national competent authorities, and several other decentralized EU entities is centered on the European Medicines Agency (EMA).  To protect its citizens' health and establish the best possible pharmaceutical regulatory environment, the Agency collaborates closely with its European partners.  The primary objective of pharmacovigilance was to guarantee that summaries and individual case safety reports were processed and submitted up to this point. When proactive detection of safety concerns (also known as "signals") and implementation of measures to reduce or mitigate patient risk are the main goals of pharmacovigilance.  This change occurred particularly quickly during the early 2000s. ⁽¹⁵⁾ \

9. Possible effects of incorporating artificial intelligence into safety surveillance.

By altering how adverse events are recognized, investigated, and managed throughout the pharmaceutical product development process, Drug safety surveillance could be greatly impacted by artificial intelligence (AI).  Recent developments demonstrate the various ways in which artificial intelligence (AI) technology can be used to enhance the effectiveness, accuracy, and lucidity of pharmacovigilance protocols.  Artificial intelligence (AI) algorithms can evaluate vast amounts of organized and unstructured data from a range of sources, such as social media, wearable technologies, medical literature, and electronic health records (EHRs).  To assess real-world data and find potential signs of (ADRs), for instance Artificial intelligence (AI) is used more successfully by IBM Watson for Drug Safety than by conventional techniques.  Interpretable Deep Learning for Liver Damage Caused by Drugs is one example of an explainable AI architecture that provides lucid insights into predictions made by AI boost stakeholder trust.  To predict drug-induced liver injury events, Stanford University researchers developed the IDILI framework^{. (5)} The researchers use observable attributes derived from molecular structures and biological pathways to explain the model's predictions.  By offering information on drug safety profiles and patient outcomes in practical settings, the FDA's Sentinel Initiative is one instance of how the inclusion of real-world data (RWD) enhances traditional clinical trial data.  The FDA’s Sentinel Initiative uses AI and machine learning algorithms to evaluate RWD from electronic health databases to track pharmaceutical safety and identify potential side effects in real time.  Records of adverse events from databases, including the FDA Adverse Event Reporting System can be subjected to temporal pattern mining approaches. to uncover long-term patterns and new safety concerns^{. (5)}  Research published in Pharmacological Safety used temporal pattern mining algorithms to analyze FAERS adverse event data and identify temporal clusters of adverse events associated with specific medications or pharmacological classes.  Distributed AI frameworks preserve data privacy while enabling secure collaboration and knowledge sharing.  Federated learning platforms, such as the Pharm AI consortium, are instances of these systems. The Pharm AI cooperation developed a federated learning platform that protects sensitive patient data while allowing pharmaceutical companies, regulatory agencies, and healthcare providers to collaborate on training AI models on distributed datasets. ⁽⁵⁾  Finding predictive biomarkers for pharmaceutical safety with machine learning algorithms enables personalized risk assessment and treatment approaches. Machine learning algorithms were used in a study to identify genetic variants associated with assess patients' risk of liver damage brought on by drugs and create predictive biomarker panels. undergoing specific therapeutic interventions.  NLP systems for adverse event report analysis are the best examples of how natural language understanding (NLU) techniques facilitate automated case processing and signal detection. A study team developed A system that uses Analysis using natural language processing and summarize adverse data event that are sent to regulatory agencies to speed up the identification of potential safety signals. ⁽⁵⁾  There is an improvement in the evaluation of the causal relationship to drugs and adverse outcomes. Employing causal graph models and empirical data, the approach predicts the causative impact of pharmaceuticals on specific adverse occurrences, enabling more accurate assessments of drug safety profiles.  By using semi-supervised and active learning techniques, data labeling is optimized, and AI models for adverse event detection are built more quickly.  Active learning approaches that rank adverse event reports according to their possible relevance and i improve the performance of AI-based signal detection systems^{. (5)}

10. Limitations: 

Accessibility and data quality

• AI systems on sizable, representative Pharmacovigilance often comes from diverse sources (electronic health records, clinical trials, spontaneous reports) that may be incomplete, inconsistent, or biased, thus compromising accuracy in detecting adverse drug reactions (ADRs) 
• Underreporting or over reporting—often driven by media attention or population differences—can distort AI-driven analyses. 

Transparency and Explain ability  

• Many powerful AI models, especially Deep learning involves "black boxes" that make decisions in an opaque manner.
• Transparency undermines confidence and regulatory acceptance, since safety signals must be auditable and justifiable for clinical review and legal purposes. 
• Explainable AI is needed to ensure outputs can be validated and trusted by pharmacovigilance professionals. 

Bias and Equity Issues 

• Training AI on unrepresentative datasets can introduce bias, resulting in poor performance for underrepresented groups and inequitable drug safety monitoring. 
• Certain populations (e.g., minorities, rural communities) may not be well-represented in pharmacovigilance reporting, leading to missed safety signals or misclassification of risks.

Regulatory, Ethical, and Privacy Concerns 

• Responsible use demands robust data handling protocols, anonymization techniques, and      clear accountability in case of AI-related error or harm.
• Regulation is evolving but may lag technical advances, risking gaps in oversight conflicting standards.  Technical and Infrastructure Barriers  
• Heterogeneous data, ambiguity in drug and event nomenclature, local language diversity, and missing information pose challenges for AI-based data processing and labeling
• Reliable AI deployment requires robust research, financial support, and ongoing validation to ensure results are reproducible and trustworthy in real-world settings.

11. COVID?19 AND CHALLENGES

The efficiency of PvP has grown during the past few decades because of the digitization of medical data and information.  Nevertheless, the COVID-19 pandemic presented unexpected difficulties in the field of pharmacovigilance.  The physicians were forced to use both new medications (remdesivir) and repurposed ones (hydroxychloroquine and lopinavir/ritonavir).  During the pandemic, many medications were authorized for emergency use, and post-marketing pharmacovigilance played a crucial role in guaranteeing long-term patient safety.  Observational data must be used to make choices in the absence of proof from carefully carried out randomized controlled studies.  Vaccines against COVID-19 required a similar strategy^{. (1)} The epidemic has brought to light the importance of analyzing real-world data more quickly and efficiently to create evidence that can direct regulatory actions. Integration, privacy, and data quality challenges need to be addressed, though, if Big Data is to reach its full potential in enhancing prescription safety monitoring.  As the industry advances, pharmacovigilance will need to include big data as a crucial tool to guarantee pharmaceutical products' efficacy and safety.  Big data has many benefits for pharmacovigilance, but there are still obstacles in the way of its efficient application The consistency and quality of the data are among the primary problems since it might be difficult to effectively gather and assess the information from various data sources since they may utilize different formats.  Patient privacy concerns also raise moral and legal questions, particularly when it comes to unstructured data from social media and other sources. Making sure laws such as the Regulation of General Data Protection are followed is crucial for preserving patient anonymity and trust in pharmacovigilance data. Moreover, another challenge is data integration.  Pharmacovigilance requires the seamless integration of data from various sources for Big Data to be useful^{. (1)} To accomplish this, regulatory bodies, healthcare providers, and pharmaceutical firms should guarantee system compatibility and standardize data formats^{. (4)} Artificial intelligence (AI) can be used in pharmacies to improve patient outcomes and pharmaceutical safety monitoring.  Issues with data quality and availability are the most significant since they directly affect the accuracy and dependability of AI-driven forecasts and analysis.  Inaccuracies, biases, data silos, and insufficient data reporting make it difficult to conduct the thorough analysis needed for efficient pharmacovigilance.  Issues with data availability and quality might negatively impact patient outcomes and postpone regulatory action^{. (1)} The occurrences with Essure and Vioxx (forecoxa) are instances of real-world encounters.  Furthermore, interpretability and transparency present serious difficulties; intricate AI models can occasionally function being "black boxes," which makes it challenging for interested parties to understand the decisions made These issues are complicated by regulatory compliance absence of established assessment instruments, algorithmic bias, and call for substantial thought and systematic procedures.  Compatibility issues, data fragmentation, and standardization must be fixed if artificial intelligence is to be used in pharmacovigilance to its fullest extent.  It is essential to support cooperation between stakeholders, technology developers, and regulators to enhance data quality, promote transparency, and satisfy legal responsibilities.  By overcoming these obstacles and constraints, pharmacovigilance powered by AI might improve healthcare outcomes and patient safety globally by the choices made.  Regulatory compliance, a lack of standardized evaluation tools, and algorithmic bias all make these problems more challenging. which necessitate methodical processes and careful consideration.  Standardization, technology compatibility, and data fragmentation issues need to be fixed if artificial intelligence in pharmacovigilance is to reach its full potential. Encouraging cooperation between stakeholders, technology developers, and regulators is essential to upholding legal requirements, fostering transparency, and improving data quality.  Pharmacovigilance powered by AI can enhance patient safety and medical results globally by overcoming these obstacles^{. (1)}

12. Prospects for the future and suggestions for further study and advancement in AI integration with medication safety

Prospects for the Future: The future of PvP seems bright with the groundbreaking advent of artificial intelligence.  The FDA, or in the US, the Food and Drug Administration has accurately noted that the assistance of specialists in drug safety should be employed sparingly when dealing with complex pharmacovigilance issues that affect public health^.(1) Effective machine learning systems can save The amount of time an expert spent compiling and arranging information from each case safety report as well as detecting, validating, analyzing, and prioritizing signals.  Finding and eliminating duplicate data can be the first step.  Furthermore, disproportionality analysis classifies drug-event pairings, as well as identifying risk factors and drug-drug interactions.  can be aided by artificial intelligence.  Programs for machine learning can create statistics prediction models for signal detection and additional support for regulatory information language processing. ⁽¹⁾ Despite the fact that the present PvP algorithms do not meet the reliability requirements for complete automation, the field has made remarkable strides. By empowering them to make better decisions, accurate health data can help physicians, patients, and other stakeholders enhance their quality of life.  Better technologies, such natural language processing (NLP) software that can analyze unstructured patient records, have made it possible for artificial intelligence (AI) to collect patient data more effectively.  This has provided us with a wealth of information to evaluate quality, enhance methods, and enhance patient outcomes.  AI also facilitates pharmacovigilance (PV) by cutting cycle times and case processing expenses.  Pharmacovigilance can benefit greatly from machine learning and artificial intelligence.  What started off as information sharing and data gathering for regulatory bodies is now developing into a system that enhances the risk-benefit profiles of medications, enabling ⁽⁷⁾ Future outlooks and suggestions for further study and advancements in the combination of AI and pharmacovigilance AI in pharmacovigilance offers promising prospects that will revolutionize drug safety management and monitoring in the future.  AI technology can increase the efficacy and accuracy monitoring and analyzing large datasets in real time from multiple sources. These systems' quicker and more precise recognition of patterns, trends, and potential risks than more traditional methods enable proactive measures to lessen harm.  Moreover, AI-driven predictive analytics may enable regulatory bodies and medical professionals to respond quickly and forcefully to escalating safety concerns ⁽⁵⁾ Additionally, integrating AI could improve pharmacovigilance reporting requirements and speed up regulatory processes for compliance All things considered, pharmacovigilance using AI offers a ground-breaking approach to enhance medication safety monitoring and safeguard the general public's health.  The following recommendations have been put up for additional research and development to successfully apply AI in pharmacovigilance.  By following these recommendations, pharmacovigilance stakeholders can take advantage of the ground-breaking potential of artificial intelligence technology to enhance FDA decision-making, medication safety monitoring, and patient care. As safer and more efficient medications become available, these efforts will improve public health worldwide. ⁽⁵⁾

13. CONCLUSION

Pharmacovigilance is essential for preserving drug safety and safeguarding the general public's health, particularly considering the quick development of new medications.  The detection, analysis, and prevention of adverse medication responses have changed dramatically results of the combination of artificial intelligence (AI) and big data.  Real-time monitoring, predictive analysis, and more precise risk identification before patients are harmed are all made feasible by these technologies.  Nevertheless, problems including data quality, privacy concerns, ethical dilemmas, and the requirement for uniform international standards still exist despite these developments.  To effectively utilize AI's potential in pharmacovigilance, these constraints must be addressed.  Collaboration between researchers, regulatory bodies, technology developers, and healthcare professionals will be essential going forward.  Pharmacovigilance can be made more effective by fusing AI-driven solutions with human expertise. Pharmacovigilance can be made more effective, transparent, and proactive with AI-driven solutions, guaranteeing safer pharmaceutical use and better patient outcomes everywhere. An important development in drug safety monitoring is the incorporation of artificial intelligence into pharmacovigilance, which improves the accuracy of adverse event identification and allows for earlier risk detection.  AI-driven solutions are increasing the effectiveness, scalability, and precision of pharmaceutical product monitoring across a range of populations by leveraging massive data resources and automation.  Notwithstanding these developments, there are still issues with data quality, openness, interoperability, and regulatory alignment that call for constant cooperation between oversight organizations, digital entrepreneurs, and stakeholders.  By addressing these constraints, AI's full potential can be realized, resulting in safer medical procedures and improved public health protection.  AI-powered pharmacovigilance will continue to be a fundamental pillar for medication safety and patient care worldwide as the area develops thanks to ongoing research and system improvement.

REFERENCES

1. Paul AE, Sasidharanpillai S. Role of Pharmacovigilance in Drug Safety Monitoring. Indian Dermatology Online Journal. 2025 Jul 1;16(4):545-50.
2. Komi LS, Mustapha AY, Forkuo AY, Osamika D. Reviewing Pharmacovigilance Strategies Using Real-World Data for Drug Safety Monitoring and Management (2025)
3. Jaibhagvan J. Pharmacovigilance in the Digital Age: Using Big Data and Artificial Intelligence to Improve Drug Safety. Scholar’s Digest: Journal of Pharmacology. 2025 Apr 16;1(1):170-86.
4. Rashmi R, Kaur V, Kumar A, Srivastava H, Kumar S, Babu A. AI-Powered Pharmacovigilance: Revolutionizing Drug Safety for Tomorrow. Available at SSRN 5086737. 2024 Nov 15.
5. Ahire YS, Patil JH, Chordiya HN, Deore RA, Bairagi VA. Advanced applications of artificial intelligence in pharmacovigilance: Current trends and future perspectives. J Pharm Res. 2024 Jan;23(1):23-33.
6. Potter K, KARL L. Machine Learning in Drug Safety Monitoring: Enhancing Pharmacovigilance Efforts. (2023)
7. Pandey V, Khanum AF, Alfisha SM, Sethiya NK, Kumar B. Revolutionizing drug safety: the role of AI in pharmacovigilance. World J Pharm Res. 2023 Apr 20;12(9):2319-33.
8. Ogbuagu OO, Mbata AO, Balogun OD, Oladapo O, Ojo OO, Muonde M. Artificial intelligence in clinical pharmacy: Enhancing drug safety, adherence, and patient-centered care. International Journal of Multidisciplinary Research and Growth Evaluation. 2023 Jan;4(1):814-22.
9. Javed Z. The Role of Pharmacovigilance in Ensuring Drug Safety. American Journal of Pharmaceutics. 2020 Aug 31;1(4):15-28
10. Basile AO, Yahi A, Tatonetti NP. Artificial intelligence for drug toxicity and safety. Trends in pharmacological sciences. 2019 Sep 1;40(9):624-35.
11. Pitts PJ, Le Louet H. Advancing drug safety through prospective pharmacovigilance. Ther Innov Regul Sci. 2018; 52 (4): 400–2 [Internet].
12. Laporte JR. Fifty years of pharmacovigilance–medicines safety and public health. Pharmacoepidemiology and drug safety. 2016 Jun;25(6):725-32.
13. Härmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, Kant A. Patient-reported safety information: a renaissance of pharmacovigilance?. Drug safety. 2016 Oct;39(10):883-90.
14. Gershman JA, Fass AD. Medication safety and pharmacovigilance resources for the ambulatory care setting: enhancing patient safety. Hospital pharmacy. 2014 Apr;49(4):363-8.
15. Jacob D, Marrón B, Ehrlich J, Rutherford PA. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug, healthcare and patient safety. 2013 Apr 15:105-12.
16. Härmark L, van Grootheest A. Pharmacovigilance: methods, recent developments and future perspectives. European journal of clinical pharmacology. 2008 Aug;64(8):743-52.